Studies of pharmacogenetics testing of pharmacy students as a teaching tool, an improved system to resolve medication issues after patients go home from the hospital, and the prophylactic use of an antiseizure drug for brain surgery patients took top honors at the Department of Clinical Pharmacy 18th Annual Spring Research Seminar.
Spiked rods of uric acid crystals from synovial fluid photographed under a microscope with polarized light. In patients with gout, such crystals can accumulate in the joints, causing pain and inflammation.
Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.
My primary interest is identification of genetic determinants of drug response through modern methods aimed at addressing pharmacogenomics research and translating that information into new diagnostics and treatment strategies at point-of-care.
I teach and precept pharmacy students and work with underserved populations at San Francisco General Hospital. My research focuses on the clinical application of cardiovascular pharmacogenetic tests and pharmacoepidemiology.
My work focuses on the translation of new technologies into improved patient outcomes, particularly the translation of personalized/precision medicine—targeting health care interventions to patients based on their genetics—into clinical care and health policy.
My research seeks to understand the contribution of genetic variation to drug toxicity, to identify genetic biomarkers that can be used to guide effective use of drugs in the treatment of cancer and HIV, and to use genetics to unravel the molecular basis of drug-induced toxicity.
My research focuses on membrane transporters, which are of great importance to drug disposition and response. I am particularly interested in genetic variants in membrane transporters that are determinants of drug response and in harnessing transporters to enhance drug targeting.
Pharmacogenetics expert Kathy Giacomini, PhD, co-chair of the UCSF Department of Bioengineering and Therapeutic Sciences, is leading the UCSF arm of a research partnership in which her team will profile 2,000 prescription drugs against key molecules in the liver and kidney that are responsible for ferrying those dr
Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine, will receive the 2010 Therapeutic Frontiers Lecture Award from the American College of Clinical Pharmacy on October 17, 2010, in Austin, Texas at ACCP's annual meeting.